Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
January 10, 2026
Approximately 5 minutes
Swiss Authorised Representative (CH-REP) for Medical Devices – Swissmedic Obligations
Swiss Authorised Representative (CH-REP) for Medical Devices – Swissmedic Obligations
Legal Requirement and Purpose
Since the entry into force of the revised Medical Devices Ordinance (MedDO) on 26 May 2021, manufacturers without a registered place of business in Switzerland must appoint a Swiss Authorised Representative (CH-REP) to place their medical devices on the Swiss market. The CH-REP acts as the legal entity in Switzerland responsible for ensuring regulatory compliance on behalf of the foreign manufacturer, similar to the role of an EU Authorised Representative under MDR/IVDR. This requirement strengthens market surveillance, traceability, and direct communication with Swissmedic. CH-REP – Swissmedic
Who Needs a CH-REP
A CH-REP is mandatory for:
- All non-Swiss manufacturers placing devices of any class (including custom-made and investigational devices under certain conditions) on the Swiss market.
- Importers and distributors are not required to act as CH-REP unless they assume manufacturer obligations.
Swiss-based manufacturers do not need a CH-REP.
Appointment and Designation
- The foreign manufacturer must formally designate the CH-REP via a written mandate/agreement.
- The CH-REP must be a natural or legal person established in Switzerland with sufficient competence and resources.
- The designation must be documented and made available to Swissmedic upon request.
The CH-REP's details (name, address, contact) must appear on the device labelling, instructions for use, and declarations of conformity.
Key Responsibilities of the CH-REP
The CH-REP assumes the following obligations on behalf of the manufacturer:
- Technical Documentation: Keep available for Swissmedic for the required retention period.
- Vigilance and Post-Market Surveillance: Handle incident reporting, field safety corrective actions, and trend reporting.
- Registration: Support or perform registrations in the Swiss medical devices database (including UDI data where applicable).
- Liaison: Serve as the primary contact for Swissmedic enquiries and inspections.
- Compliance Monitoring: Ensure ongoing conformity with MedDO requirements, including updates to labelling and documentation.
- Language: Ensure Swiss-required language versions (German, French, Italian) are available.
The manufacturer remains ultimately responsible for device safety and compliance; the CH-REP acts as a mandated agent.
Practical Considerations
- Multiple manufacturers may appoint the same CH-REP.
- Changes in CH-REP designation require prompt notification to Swissmedic and update of affected documentation/labelling.
- Swissmedic provides guidance on mandate templates, minimum competence requirements, and a public list of registered CH-REPs for verification.
This mandatory CH-REP system aligns Switzerland's framework with international standards while ensuring effective national oversight and patient safety for imported medical devices. Detailed obligations, mandate examples, and contact information are available on the Swissmedic CH-REP dedicated page. CH-REP – Swissmedic
Ask Anything
We'll follow up with you personally.
Related Articles
Approximately 5 minutes
Notification of Medical Devices Placed on the Swiss Market – Swissmedic Procedure
Swissmedic requires notification of all medical devices placed on the Swiss market via the mandatory registration in the Product Registration Database, replacing the former notification system with a comprehensive electronic process that includes device details, economic operator information, UDI where applicable, and vigilance data to support market surveillance and traceability under the revised MedDO.
Approximately 5 minutes
Notification of In Vitro Diagnostic Devices Placed on the Swiss Market – Swissmedic Requirements
Swissmedic mandates registration (serving as notification) of all in vitro diagnostic (IVD) medical devices placed on the Swiss market in the Product Registration Database, requiring submission of UDI data, economic operator details, conformity documentation, and classification information to enable traceability, vigilance, and regulatory oversight under the revised MedDO and IVDR-aligned framework.
Approximately 5 minutes
Notification Procedure for Devitalised Human Tissue Products in Switzerland – Swissmedic Guidance
Swissmedic requires notification of devitalised human tissue products (allografts without viable cells) placed on the Swiss market, classifying them as medical devices under specific MedDO provisions, with mandatory submission of product details, donor screening, processing information, and conformity data to ensure safety, traceability, and regulatory oversight prior to distribution.